Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07242482Not Yet Recruiting

Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients

Role: lead

NCT07047573Recruiting

Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules

Role: lead

NCT06790797Recruiting

Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients

Role: lead

NCT05789498Unknown

Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients

Role: lead

All 4 trials loaded